Principal Financial Group Inc. Purchases 8,980 Shares of Bruker Corporation $BRKR

Principal Financial Group Inc. raised its position in shares of Bruker Corporation (NASDAQ:BRKR) by 3.8% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 247,383 shares of the medical research company’s stock after purchasing an additional 8,980 shares during the quarter. Principal Financial Group Inc.’s holdings in Bruker were worth $8,935,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in BRKR. Royal Bank of Canada increased its position in shares of Bruker by 8.3% in the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after acquiring an additional 9,501 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Bruker during the first quarter worth about $262,000. Goldman Sachs Group Inc. boosted its holdings in shares of Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after purchasing an additional 758,301 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after purchasing an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth grew its stake in shares of Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after purchasing an additional 6,008 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

BRKR stock opened at $60.45 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.54. The firm has a 50-day moving average of $56.32 and a 200 day moving average of $46.29. The company has a market cap of $9.20 billion, a P/E ratio of -251.88, a PEG ratio of 1.94 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same period in the previous year, the firm posted $0.47 EPS. The business’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts forecast that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s dividend payout ratio is presently -83.33%.

Analysts Set New Price Targets

BRKR has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on Bruker in a research report on Monday, June 1st. They set a “peer perform” rating for the company. Stifel Nicolaus set a $45.00 price objective on Bruker in a research report on Friday, May 8th. UBS Group set a $60.00 target price on Bruker in a research note on Wednesday, June 24th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, Leerink Partners raised their price target on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $56.79.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.